8 [60] A. Celeste, S. Diﬁlippantonio, M. J. Diﬁlippantonio et al., “H2AX haploinsuﬃciency modiﬁes genomic stability and tumor susceptibility,” Cell, vol. 114, no. 3, pp. 371–383, 2003. [61] S. Petersen, R. Casellas, B. Reina-San-Martin et al., “AID is required to initiate Nbs1/γ-H2AX focus formation and mutations at sites of class switching,” Nature, vol. 414, no. 6864, pp. 660–665, 2001. [62] C. H. Bassing, K. F. Chua, J. Sekiguchi et al., “Increased ioniz- ing radiation sensitivity and genomic instability in the absence of histone H2AX,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 12, pp. 8173–8178, 2002. [63] B. Reina-San-Martin, S. Diﬁlippantonio, L. Hanitsch, R. F. Masilamani, A. Nussenzweig, and M. C. Nussenzweig, “H2AX is required for recombination between immunoglobulin switch regions but not for intra-switch region recombination or somatic hypermutation,” Journal of Experimental Medicine, vol. 197, no. 12, pp. 1767–1778, 2003. [64] A. Xie, N. Puget, I. Shim et al., “Control of sister chromatid recombination by histone H2AX,” Molecular Cell, vol. 16, no. 6, pp. 1017–1025, 2004. [65] J. Kao, M. T. Milano, A. Javaheri et al., “γ-H2AX as a therapeutic target for improving the eﬃcacy of radiation therapy,” Current Cancer Drug Targets, vol. 6, no. 3, pp. 197– 205, 2006. [66] S. Franco, M. Gostissa, S. Zha et al., “H2AX prevents DNA breaks from progressing to chromosome breaks and translocations,” Molecular Cell, vol. 21, no. 2, pp. 201–214, 2006. [67] A. R. Ramiro, M. Jankovic, E. Callen et al., “Role of genomic instability and p53 in AID-induced c-myc-Igh translocations,” Nature, vol. 440, no. 7080, pp. 105–109, 2006. [68] A. Kinner, W. Wu, C. Staudt, and G. Iliakis, “Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin,” Nucleic Acids Research, vol. 36, no. 17, pp. 5678–5694, 2008. [69] S. Matsuoka, B. A. Ballif, A. Smogorzewska et al., “ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage,” Science, vol. 316, no. 5828, pp. 1160–1166, 2007. [70] S. Sakamoto, K. Iijima, D. Mochizuki et al., “Homologous recombination repair is regulated by domains at the N- and C-terminus of NBS1 and is dissociated with ATM functions,” Oncogene, vol. 26, no. 41, pp. 6002–6009, 2007. [71] C. H. Bassing and F. W. Alt, “H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity,” Cell Cycle, vol. 3, no. 2, pp. 149–153, 2004. [72] C. Sjo¨gren and K. Nasmyth, “Sister chromatid cohesion is required for postreplicative double-strand break repair in Saccharomyces cerevisiae,” Current Biology, vol. 11, no. 12, pp. 991–995, 2001. [73] E. Sonoda, T. Matsusaka, C. Morrison et al., “Scc1/Rad21/Mcd1 is required for sister chromatid cohesion and kinetochore function in vertebrate cells,” Developmental Cell, vol. 1, no. 6, pp. 759–770, 2001. [74] J.-S. Kim, T. B. Krasieva, V. LaMorte, A. M. Taylor, and K. Yokomori, “Speciﬁc recruitment of human cohesin to laser- induced DNA damage,” Journal of Biological Chemistry, vol. 277, no. 47, pp. 45149–45153, 2002. [75] N. F. Lowndes and G. W.-L. Toh, “DNA repair: the importance of phosphorylating histone H2AX,” Current Biology, vol. 15, no. 3, pp. R99–R102, 2005. Journal of Nucleic Acids [76] O. Ostling and K. J. Johanson, “Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells,” Biochemical and Biophysical Research Communications, vol. 123, no. 1, pp. 291–298, 1984. [77] A. R. Collins, A. A. Oscoz, G. Brunborg et al., “The comet assay: topical issues,” Mutagenesis, vol. 23, no. 3, pp. 143–151, 2008. [78] D. G. McArt, G. McKerr, C. V. Howard, K. Saetzier, and G. R. Wasson, “Modelling the comet assay,” Biochemical Society Transactions, vol. 37, no. 4, pp. 914–917, 2009. [79] X. Huang, H. D. Halicka, F. Traganos, T. Tanaka, A. Kurose, and Z. Darzynkiewicz, “Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis,” Cell Proliferation, vol. 38, no. 4, pp. 223–243, 2005. [80] Z. Darzynkiewicz, X. Huang, and M. Okafuji, “Detection of DNA strand breaks by ﬂow and laser scanning cytometry in studies of apoptosis and cell proliferation (DNA replication),” Methods in Molecular Biology, vol. 314, pp. 81–93, 2006. [81] J. A. Downs, “Chromatin structure and DNA double-strand break responses in cancer progression and therapy,” Oncogene, vol. 26, no. 56, pp. 7765–7772, 2007. [82] N. Taneja, M. Davis, J. S. Choy et al., “Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy,” Journal of Biological Chemistry, vol. 279, no. 3, pp. 2273–2280, 2004. [83] J. Bartkova, Z. Horˇejsˇ´ı, K. Koed et al., “DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis,” Nature, vol. 434, no. 7035, pp. 864–870, 2005. [84] T. D. Halazonetis, V. G. Gorgoulis, and J. Bartek, “An oncogene-induced DNA damage model for cancer develop- ment,” Science, vol. 319, no. 5868, pp. 1352–1355, 2008. [85] J. Campisi, “Suppressing cancer: the importance of being senescent,” Science, vol. 309, no. 5736, pp. 886–887, 2005. [86] L. J. Kuo and L.-X. Yang, “γ-H2AX—a novel biomaker for DNA double-strand breaks,” In Vivo, vol. 22, no. 3, pp. 305– 310, 2008. [87] O. A. Sedelnikova and W. M. Bonner, “γH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence,” Cell Cycle, vol. 5, no. 24, pp. 2909–2913, 2006. [88] V. G. Gorgoulis, L.-V. F. Vassiliou, P. Karakaidos et al., “Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions,” Nature, vol. 434, no. 7035, pp. 907–913, 2005. [89] I. B. Roninson, “Tumor cell senescence in cancer treatment,” Cancer Research, vol. 63, no. 11, pp. 2705–2715, 2003. [90] P. V. Rekhadevi, N. Sailaja, M. Chandrasekhar, M. Mahboob, M. F. Rahman, and P. Grover, “Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs,” Mutagenesis, vol. 22, no. 6, pp. 395–401, 2007. [91] C. H. Bassing, H. Suh, D. O. Ferguson et al., “Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors,” Cell, vol. 114, no. 3, pp. 359–370, 2003. [92] K. L. Novik, J. J. Spinelli, A. C. Macarthur et al., “Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 6, pp. 1098–1106, 2007. [93] J. Lu, Q. Wei, M. L. Bondy et al., “Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged ≤55 years,” Breast Cancer Research and Treatment, vol. 110, no. 2, pp. 357– 366, 2008.